Form 4: Beta Bionics CFO Sells Shares After Option Exercise

Beta Bionics' Chief Financial Officer, Stephen Feider, sold 5,587 shares of common stock for $17.0345 per share after exercising options, as part of a pre-arranged trading plan.

Summary

• Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), exercised employee stock options to acquire 5,587 shares of common stock at an exercise price of $5.10 per share on August 19, 2025.
• Concurrently, Feider sold all 5,587 newly acquired shares of common stock at a weighted average price of $17.0345 per share, with prices ranging from $17.00 to $17.095, on August 19, 2025.
• The sale was executed under a Rule 10b5-1 trading plan that was adopted on May 15, 2025.
• Following these transactions, Feider's direct beneficial ownership of common stock decreased from 51,090 shares to 45,503 shares.
• His beneficial ownership of employee stock options (right to buy) decreased by the exercised amount, leaving 104,108 derivative securities.

Sentiment

Score: 6

Explanation: The transaction involves an executive exercising options and immediately selling the acquired shares. The sale was conducted under a pre-arranged Rule 10b5-1 plan, which reduces the negative signal typically associated with insider sales, as it indicates a planned liquidity event rather than a reaction to new, adverse information. The significant profit from the option exercise is a positive for the executive and reflects past stock appreciation.

Positives

• The exercise of options indicates the executive is realizing value from their compensation, which can be a sign of confidence in the company's long-term performance.
• The sale was conducted under a pre-arranged Rule 10b5-1 plan, which suggests the transaction was not based on new, non-public information and is a routine liquidity event.
• The significant difference between the exercise price ($5.10) and the sale price ($17.0345) indicates a substantial gain for the executive, reflecting an increase in the company's stock value.

Negatives

• The sale of shares by a Chief Financial Officer, even if pre-planned, reduces their direct equity stake in the company, which could be perceived as a slight reduction in alignment with shareholder interests.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by a CFO, even if pre-planned, slightly reduces the executive's direct equity alignment. However, the pre-planned nature mitigates concerns about adverse insider information. The transaction itself does not directly impact other stakeholders like employees, customers, suppliers, or creditors.

Key Dates

Recommendation

The filing details a routine, pre-planned transaction by a corporate officer involving the exercise of stock options and the subsequent sale of shares. This type of transaction, executed under a Rule 10b5-1 plan, is generally not indicative of new material information about the company's prospects. While an insider sale reduces the executive's direct equity stake, the pre-planned nature suggests it's for personal financial planning rather than a bearish signal. Therefore, this specific filing alone does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position is appropriate as it does not alter the fundamental investment thesis.

Keywords

Beta Bionics, BBNX, Stephen Feider, CFO, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Corporate Officer, Equity Compensation